Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

NeuroGen Pharma Secures Exclusive China Rights to Teva’s Ajovy – World’s First Dual-Indication CGRP Antagonist for Migraine Prevention

Fineline Cube Apr 22, 2026
Company Deals

Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma

Fineline Cube Apr 21, 2026
Company Deals Digital

AI Healthtech Firm WeiMai Files for Hong Kong IPO, Touting CareAI Platform and Leadership in Hospital-Linked Disease Management

Fineline Cube Apr 21, 2026
Company Deals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

Fineline Cube Apr 21, 2026
Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Fineline Cube Apr 21, 2026
Company Drug

AstraZeneca’s Ultomiris Shows Significant Proteinuria Reduction in Phase III IgA Nephropathy Trial

Fineline Cube Apr 22, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus (HB1901) Meets Primary Endpoint in Phase Ib/III Trial for Rare PEComa, Reinforcing Breakthrough Therapy Status

Fineline Cube Apr 21, 2026
Company Deals

Moderna Partners with Mitsubishi Tanabe for mRNA Vaccine Promotion in Japan

Fineline Cube Jul 9, 2024

Moderna Inc. (NASDAQ: MRNA), a leading mRNA specialist biotechnology company based in the U.S., has...

Company Deals

Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal

Fineline Cube Jul 9, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...

Company Drug

Roche’s Susvimo Implant Cleared for Relaunch in US After Voluntary Recall

Fineline Cube Jul 9, 2024

Roche (SWX: RO), the Swiss pharmaceutical giant, has announced the conclusion of the voluntary recall...

Company Medical Device

Boston Scientific’s FARAPULSE Pulse Field Ablation System Earns NMPA Approval

Fineline Cube Jul 9, 2024

Boston Scientific Corporation (NYSE: BSX), a leading medical device company in the U.S., has announced...

Company Drug

Ascentage Pharma’s Olverembatinib Receives Marketing Approval from Macau SAR for CML Treatment

Fineline Cube Jul 9, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...

Company Deals

Keymed Biosciences Strikes Licensing Deal with Belenos Biosciences for Global BsAb Rights

Fineline Cube Jul 9, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has entered into a...

Company Deals R&D

Quantum Hi-Tech Partners with East China Normal University to Establish Advanced Drug Research Lab

Fineline Cube Jul 9, 2024

Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), has entered into a...

Company Deals

China Isotope & Radiation Corporation to Establish Cancer Treatment Center in Nigeria

Fineline Cube Jul 9, 2024

China Isotope & Radiation Corporation (CIRC; HKG: 1763), a leading provider of medical equipment and...

Company Drug

Shanghai Fosun Pharmaceutical Gets NMPA Green Light for FH-2001 and Serplulimab Combo Clinical Trial

Fineline Cube Jul 9, 2024

Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a prominent pharmaceutical company in...

Company Drug

CSPC Pharmaceutical’s SYS6023 Receives FDA Approval for Clinical Study in Advanced Solid Tumors

Fineline Cube Jul 9, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Allist Pharmaceuticals Receives NMPA Approval for Phase III Trial of Furmonertinib in EGFR Mutated NSCLC

Fineline Cube Jul 9, 2024

Allist Pharmaceuticals Co., Ltd, a Shanghai-based biopharmaceutical company, has announced that it has received approval...

Policy / Regulatory

China’s State Council Reportedly Approves Plan to Support Full Industry Chain of Innovative Drug Development

Fineline Cube Jul 8, 2024

A State Council executive meeting, chaired by Chinese Premier Li Qiang, reportedly approved an “Implementation...

Company Drug

AusperBio’s AHB-137 Antiviral Candidate on Path to Breakthrough Designation for Chronic Hepatitis B in China

Fineline Cube Jul 8, 2024

AusperBio, a sino-American developer specializing in liver therapies, has announced that its drug candidate AHB-137...

Company Drug

Yantai Dongcheng Pharmaceutical Gets NMPA Approval for ⁹⁹ᵐTc Tetrofosmin Imaging Agent

Fineline Cube Jul 8, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has...

Company Drug

Shenzhen Salubris Pharmaceuticals’ Fotagliptin Receives NMPA Approval for Type 2 Diabetes Treatment

Fineline Cube Jul 8, 2024

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a pharmaceutical company based in China, has announced...

Company Drug

Roche’s Alecensa Secures NMPA Approval as Adjuvant Therapy for Early-Stage NSCLC

Fineline Cube Jul 8, 2024

Roche (SWX: RO), the Swiss pharmaceutical giant, has announced that it has received an additional...

Company Drug

Immorna Earns FDA Approval for Phase I/II Clinical Trial of Self-Replicating RNA Cancer Therapy

Fineline Cube Jul 8, 2024

Immorna (Hangzhou) Biotechnology, a biotech company specializing in mRNA-based vaccines and located in Hangzhou, has...

Company Drug

Novo Nordisk’s Esperoct Receives NMPA Approval, First Long-Acting Factor VIII for Hemophilia A in China

Fineline Cube Jul 8, 2024

The National Medical Products Administration (NMPA) has granted approval to Novo Nordisk (NYSE: NVO), a...

Company Deals Medical Device

Xinzeyuan Medical Technology Secures Over RMB 100 Million in Series B Financing

Fineline Cube Jul 8, 2024

Xinzeyuan Medical Technology Co., Ltd, a Hangzhou-based micro invasive medical device supply chain platform, has...

Company Deals Drug

Innovent Biologics and IASO Biotherapeutics Amend Partnership, Focusing on CAR-T Therapy Fucaso

Fineline Cube Jul 8, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced a...

Posts pagination

1 … 322 323 324 … 654

Recent updates

  • AstraZeneca’s Ultomiris Shows Significant Proteinuria Reduction in Phase III IgA Nephropathy Trial
  • China’s Drug Quality Control System Shows 99.5% Compliance Rate in 2025 NMPA Report
  • NeuroGen Pharma Secures Exclusive China Rights to Teva’s Ajovy – World’s First Dual-Indication CGRP Antagonist for Migraine Prevention
  • Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma
  • CSPC’s Albumin-Bound Sirolimus (HB1901) Meets Primary Endpoint in Phase Ib/III Trial for Rare PEComa, Reinforcing Breakthrough Therapy Status
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca’s Ultomiris Shows Significant Proteinuria Reduction in Phase III IgA Nephropathy Trial

Others

China’s Drug Quality Control System Shows 99.5% Compliance Rate in 2025 NMPA Report

Company Deals

NeuroGen Pharma Secures Exclusive China Rights to Teva’s Ajovy – World’s First Dual-Indication CGRP Antagonist for Migraine Prevention

Company Deals

Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.